Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Japan Approves Forxiga® for Type 2 Diabetes

By Pharmaceutical Processing | March 24, 2014

AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, as a once-daily oral treatment for type 2 diabetes. The FORXIGA application was submitted to the MHLW by Bristol-Myers Squibb K.K.. AstraZeneca and Ono Pharmaceutical entered into an agreement to co-promote FORXIGA on 3 December 2013.

Fouzia Laghrissi-Thode, Vice President, Global Product Portfolio Strategy for Cardiovascular and Metabolism, said: “In collaboration with our partner Ono, we are pleased to provide FORXIGA as a new treatment option for patients in Japan, where there are an estimated 9.5 million people living with type 2 diabetes. The approval of FORXIGA reinforces AstraZeneca’s focus on both diabetes and Japan as two of our key growth drivers.”

FORXIGA is a highly selective and reversible inhibitor of sodium-glucose cotransporter 2 that works independently of insulin to help remove excess glucose from the body. Currently approved in more than 40 countries globally, FORXIGA was the first SGLT2 inhibitor in the world to gain regulatory approval to treat type 2 diabetes in Europe in November 2012. It was approved by the US Food and Drug Administration for the treatment of adults with type 2 diabetes on 8 January 2014, supported by a robust clinical development programme comprised of 24 clinical studies evaluating safety and efficacy of FORXIGA. The studies included more than 11,000 adults with type 2 diabetes, with more than 6,000 patients treated with dapagliflozin. The on-going global clinical development programme also includes a cardiovascular outcomes trial which aims to enroll more than 17,000 patients.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE